Brodalumab - AstraZeneca/Kyowa Hakko Kirin/Bausch Health Companies

Drug Profile

Brodalumab - AstraZeneca/Kyowa Hakko Kirin/Bausch Health Companies

Alternative Names: AMG-827; KHK-4827; Kyntheum; LP 0160; LUMICEF; SILIQ; Siliq

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bausch Health Companies; Kyowa Hakko Kirin; LEO Pharma
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Registered Psoriasis
  • Phase III Spondylarthritis
  • Phase I Systemic scleroderma
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 24 Sep 2018 Launched for Plaque psoriasis in Canada (SC)
  • 13 Sep 2018 Pooled efficacy data from the phase III AMAGINE-2 and AMAGINE-3 trials in Plaque psoriasis released by LEO Pharma
  • 31 Aug 2018 Registered for Psoriasis in Thailand (SC) (Kyowa pipeline, November 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top